Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GP chemotherapy plus camrelizumab and apatinib for liver-metastatic nasopharyngeal carcinoma (phase II)
ChiCTR2400089020Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Aug 2024
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab, Rivoceranib, gemcitabine and cisplatin in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: 9.6-month progression-free survival rate. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
camrelizumabRivoceranibgemcitabinecisplatin
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2400089020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400089020.